Co-Diagnostics price to free cash flow CODX

Market value divided by free cash flow over the last twelve months, since 2020.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 8.3×; May 2023
6-year median: 5.7×
6-year range: 2.7× to 77.0×
Peer median: 9.5×

Co-Diagnostics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in May 2023, at 8.3×.

On the days it had one over the last 6 years, its median was 5.7×, from 2.7× in Mar 2022 to 77.0× in Feb 2021.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	8.3×	5.6×	14.9×
2022	5.5×	2.7×	7.9×
2021	4.7×	4.4×	77.0×
2020	42.0×	42.0×	53.8×

Against its peers

Companies in Healthcare nearest Co-Diagnostics' size, closest first, today.

Company	Price to free cash flow
CODXCo-Diagnostics	n/m
OXBROXBRIDGE RE HOLDINGS	n/m
EDUCEducational Development	49.2×
GTIMGood Times Restaurants	5.2×
MDRRMedalist Diversified	n/m
BCGBinah Capital	3.2×
VIPVulcan Infrastructure & Power	n/m
MXCMexco Energy	13.7×
CKXCKX Lands	n/m
MSGMMotorsport Games	n/m
ATCHAtlasClear	n/m
Peer median	9.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Co-Diagnostics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.